OMER - Omeros Corporation

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
12.64
-0.20 (-1.56%)
At close: 4:00PM EST
Stock chart is not supported by your current browser
Previous Close12.84
Open12.65
Bid12.30 x 3000
Ask12.90 x 900
Day's Range12.02 - 12.90
52 Week Range8.36 - 27.00
Volume1,103,742
Avg. Volume934,015
Market Cap619.478M
Beta (3Y Monthly)4.99
PE Ratio (TTM)N/A
EPS (TTM)-1.84
Earnings DateAug 6, 2018 - Aug 10, 2018
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est40.25
Trade prices are not sourced from all markets
  • Thomson Reuters StreetEvents6 days ago

    Edited Transcript of OMER earnings conference call or presentation 9-Nov-18 1:30pm GMT

    Q3 2018 Omeros Corp Earnings Call

  • Here's Why Omeros Corporation Fell as Much as 24.5% Today
    Motley Fool8 days ago

    Here's Why Omeros Corporation Fell as Much as 24.5% Today

    The struggling drug developer reported third-quarter 2018 operating results and raised $210 million in debt.

  • Benzinga8 days ago

    The Daily Biotech Pulse: SITC Presentations Pick Up Pace, Sandoz' Voluntary Recall

    Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peak (Biotech stocks hitting 52-week highs on Nov. 8) Amphastar Pharmaceuticals Inc (NASDAQ: AMPH ) AstraZeneca ...

  • Business Wire8 days ago

    Omeros Announces Pricing of $210 Million Offering of Convertible Senior Notes Due 2023

    Omeros Corporation (OMER) (“Omeros”) today announced the pricing of an offering of $210 million aggregate principal amount of its 6.25% Convertible Senior Notes due 2023 (the “Notes”) in a private offering (the “Offering”) to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933 (the “Securities Act”). Omeros has granted the initial purchasers of the Notes an option to purchase up to an additional $40 million aggregate principal amount of the Notes on the same terms and conditions referenced above. The Notes will be senior unsecured obligations of Omeros and interest will be payable semi-annually in arrears at a rate of 6.25% per annum.

  • ACCESSWIRE8 days ago

    Today's Research Reports on Trending Tickers: Omeros and Spectrum Pharmaceuticals

    NEW YORK, NY / ACCESSWIRE / November 9, 2018 / U.S. stocks retreated on Thursday after the Fed left interest rates unchanged and signaled that it would continue to tighten monetary policy at a gradual ...

  • Omeros (OMER) Reports Q3 Loss, Tops Revenue Estimates
    Zacks8 days ago

    Omeros (OMER) Reports Q3 Loss, Tops Revenue Estimates

    Omeros (OMER) delivered earnings and revenue surprises of 1.39% and 50.34%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?

  • Associated Press9 days ago

    Omeros: 3Q Earnings Snapshot

    On a per-share basis, the Seattle-based company said it had a loss of 81 cents. Losses, adjusted for non-recurring costs, were 71 cents per share. The drug developer posted revenue of $4.6 million in the ...

  • PR Newswire9 days ago

    Omeros Announces Proposed $210 Million Offering of Convertible Senior Notes Due 2023

    SEATTLE, Nov. 8, 2018 /PRNewswire/ -- Omeros Corporation (OMER) ("Omeros") today announced its intention to offer, subject to market and other conditions, $210 million aggregate principal amount of its Convertible Senior Notes due 2023 (the "Notes") in a private offering (the "Offering") to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933 (the "Securities Act"). Omeros also intends to grant the initial purchaser of the Notes a 30-day option to purchase up to an additional $40 million aggregate principal amount of the Notes, for a total potential offering size of $250 million. The Notes will mature on November 15, 2023, unless earlier converted, repurchased or redeemed in accordance with their terms, and will be convertible, subject to the satisfaction of certain conditions, into cash, shares of Omeros' common stock or a combination thereof as elected by Omeros in its sole discretion.

  • Business Wire9 days ago

    Omeros Corporation Reports Third Quarter 2018 Financial Results

    – Conference Call Friday, November 9th at 8:30 a.m. ET –

  • Business Wire12 days ago

    Omeros Corporation to Announce Third Quarter 2018 Financial Results on November 9, 2018

    Omeros Corporation (OMER) today announced that the company will issue its third quarter 2018 financial results for the period ended September 30, 2018, on Friday, November 9, 2018, before the market opens. In addition, Omeros has a diverse group of preclinical programs and a proprietary G protein-coupled receptor (GPCR) platform through which it controls 54 new GPCR drug targets and corresponding compounds, a number of which are in preclinical development.

  • Why Omeros Corporation Fell 37.4% in October
    Motley Fool14 days ago

    Why Omeros Corporation Fell 37.4% in October

    It appears that an unproven approach to treating rare blood disorders will remain that way.

  • Business Wire25 days ago

    FDA Grants Orphan Drug Designation to Omeros’ OMS721 for Treatment of Hematopoietic Stem Cell Transplant-Associated Thrombotic Microangiopathy

    Omeros Corporation (OMER) today announced that OMS721 has received orphan drug designation from the U.S. Food and Drug Administration (FDA) for the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy (HSCT-TMA). OMS721 is Omeros’ lead human monoclonal antibody targeting mannan-binding lectin-associated serine protease-2 (MASP-2), the effector enzyme of the lectin pathway of the complement system.

  • GlobeNewswire25 days ago

    New Research: Key Drivers of Growth for Hecla Mining, Atlas Air Worldwide, Encana, Omeros, Lowe's Companies, and Oaktree Specialty Lending — Factors of Influence, Major Initiatives and Sustained Production

    NEW YORK, Oct. 23, 2018 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.

  • Motley Foollast month

    Are These Beaten-Down Clinical-Stage Biotech Stocks Buys?

    A partner walks away and trial data fails to impress. Here's what's next for these biotech upstarts.

  • Why Omeros Corporation Stock Is Bouncing Back Today
    Motley Fool2 months ago

    Why Omeros Corporation Stock Is Bouncing Back Today

    Investors are picking up the pieces after the biotech's bad news on Monday.

  • ACCESSWIRE2 months ago

    Today's Research Reports on Trending Tickers: Omeros and Sarepta Therapeutics

    NEW YORK, NY / ACCESSWIRE / October 2, 2018 / U.S. equities were mixed on Monday after the U.S. and Canada agreed to revise the current North American Free Trade Agreement. The Dow Jones Industrial Average ...

  • MarketWatch2 months ago

    Omeros stock drops 45% after kidney disease trial results

    Omeros Corp. shares dropped nearly 45% in Monday afternoon trade after the company released results from a phase 2 trial testing its OMS721 therapy in a progressive kidney disease called immunoglobulin A (IgA) nephropathy. The trial measured reductions in protein levels in patients' urine, called proteinuria, the "most reliable prognostic factor for loss of kidney function" in this disease. The most recent results were based on a group of nine patients who had not received corticosteroid treatment and had a high risk of disease progression, or "a difficult-to-treat population," according to Jonathan Barratt, professor of renal medicine at the University of Leicester. Of those individuals, median reductions in proteinuria after 12 weeks of therapy were very similar: 18.4% for OMS721 and 18% for placebo groups. Omeros continued to treat patients after 12 weeks, and of those eight patients, median proteinuria reductions were nearly 56%, the company said. Four individuals on Omeros' therapy in the dosing-extension period had reductions of between 53.9% and 67.8%, it said. The company continues to treat patients in this dosing-extension period and plans to present additional data at a future medical meeting. IgA nephropathy's most common symptoms are blood in the urine and foamy urine, according to the American Kidney Foundation, and doctors try to slow down the disease's characteristic kidney damage. It affects an estimated 1 in 1,400 individuals in the U.S. and currently has no approved treatments, according to Omeros. Omeros shares have dropped nearly 26% over the last three months, compared with a 7.7% rise in the S&P 500 and a nearly 10% rise in the Dow Jones Industrial Average .

  • Business Wire2 months ago

    Omeros Corporation Announces Additional Positive Data for OMS721 in IgA Nephropathy

    Omeros Corporation (OMER) today announced positive data from the company’s ongoing Phase 2 clinical trial of OMS721 for the treatment of renal diseases. The data are from study patients with immunoglobulin A (IgA) nephropathy, a progressively worsening kidney disease and the most common glomerulonephritis worldwide, responsible for 10 percent of all people on dialysis globally. Patients in this cohort had IgA nephropathy with high risk of progression but none received corticosteroid treatment immediately prior to or during the study – different than the cohort reported last year in which all patients initiated the study while on steroid therapy.

  • Business Wire2 months ago

    Omeros Corporation Announces Reinstatement of Pass-Through Status for OMIDRIA®

    -- CMS’ Separate Payment for Cataract Surgery Drug Resumes Today --

  • InvestorPlace2 months ago

    Best ETFs for 2018: Don’t Sweat This Quarter for the SBIO ETF

    Todd Shriber’s pick for the contest is the ALPS Medical Breakthroughs ETF (NYSEARCA:SBIO). The ALPS Medical Breakthroughs ETF (NYSEARCA:SBIO), my choice for the InvestorPlace Best ETFs for 2018 competition, is enduring its worst quarter of 2018. With just a few trading days left in the third quarter, SBIO is sporting a quarter-to-date loss of 0.2%.

  • Business Wire2 months ago

    Omeros to Present at the 2018 Cantor Global Healthcare Conference

    Omeros Corporation , today announced that Gregory A. Demopulos, M.D., chairman and chief executive officer, will present at the 2018 Cantor Global Healthcare Conference in New York next week.

  • Benzinga2 months ago

    Jim Cramer Shares Thoughts On Skyworks Solutions, Cypress Semiconductor, More

    On CNBC's "Mad Money Lightning Round ," Jim Cramer said Cypress Semiconductor Corporation (NASDAQ: CY ) is a buy. The stock should be trading higher on the Integrated Device Technology Inc (NASDAQ: ...

  • Amicus Therapeutics: Recent Developments, Financial Overview
    Market Realist2 months ago

    Amicus Therapeutics: Recent Developments, Financial Overview

    In August, the FDA approved Amicus Therapeutics’ (FOLD) Galafold for the treatment of adults with a confirmed diagnosis of Fabry disease along with an amenable galactosidase alpha gene variant. The FDA’s approval of Galafold was according to the accelerated approval process based on the decrease in KIC GL-3 (kidney interstitial capillary cell globotriaosylceramide) substrate. Studies estimate that more than 3,000 individuals in the United States have Fabry disease.

  • CNBC2 months ago

    Cramer's lightning round: Don't block the 'freight train' that is Skyworks Solutions' stock

    It's that time again! "Mad Money" host Jim Cramer rang the lightning round bell, which means he gave his take on callers' favorite stocks at rapid speed. Kemet Corp. KEM : "You know, it's a capacitor stock.

  • Business Wire2 months ago

    Omeros to Present at the Morgan Stanley Global Healthcare Conference

    Omeros Corporation , today announced that Gregory A. Demopulos, M.D., chairman and chief executive officer, will present at the 16th Annual Morgan Stanley Global Healthcare Conference in New York next week.